MEDICINOVA INC MNOV
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-18.54
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $409,657 | -$12.0M | — | -$9.8M | $41.6M |
| 2024 | — | -$11.0M | — | -$10.6M | $52.5M |
| 2023 | $1.0M | -$8.6M | — | -$7.5M | $62.4M |
| 2022 | — | -$14.1M | — | -$12.9M | $70.2M |
| 2021 | $4.0M | -$10.1M | — | -$9.4M | $83.7M |
| 2020 | — | -$13.9M | — | -$10.9M | $71.3M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -18.54 (distress)
- Working capital / assets 0.596
- Retained earnings / assets -9.621
- EBIT / assets -0.291
- Equity / liabilities 10.354
Source: SEC EDGAR filings · CIK 0001226616 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.